• Home
  •  / Obalon Therapeutics

Obalon Therapeutics

OverviewSuggest Edit

Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize treatment of chronic disease. As a company, we believe in the fundamental value of imagination and invention, combined with rigorous testing and analysis, to ensure the highest levels of safety and performance. The result is a user-focused approach that deploys the power of advanced technological thinking to support clinical treatment objectives.
TypePublic
Founded2008
HQCarlsbad, USMap
Websiteobalon.com
Employee Ratings3.1More

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)34(-5%)
Revenue (FY, 2019)$3.3 M(-63%)
Share Price (Sept 2020)$0.9 (+4%)
Cybersecurity ratingAMore

Key People/Management at Obalon Therapeutics

Mark Brister

Mark Brister

VP of R&D
Nooshin Hussainy

Nooshin Hussainy

Financial Controller
Show more

Obalon Therapeutics Office Locations

Obalon Therapeutics has an office in Carlsbad
Carlsbad, US (HQ)
5421 Avenida Encinas f
Show all (1)

Obalon Therapeutics Financials and Metrics

Obalon Therapeutics Revenue

Embed Graph
View revenue for all periods
Obalon Therapeutics's revenue was reported to be $3.30 m in FY, 2019
USD

Revenue (Q2, 2020)

700.0k

Gross profit (Q2, 2020)

277.0k

Gross profit margin (Q2, 2020), %

39.6%

Net income (Q2, 2020)

(4.2m)

EBIT (Q2, 2020)

(4.2m)

Market capitalization (18-Sept-2020)

7.0m

Closing stock price (18-Sept-2020)

0.9

Cash (30-Jun-2020)

6.8m

EV

661.8k
Obalon Therapeutics's current market capitalization is $7 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

3.4m9.9m9.1m3.3m

Cost of goods sold

2.8m4.8m5.4m3.0m

Gross profit

584.0k5.1m3.7m350.0k

Gross profit Margin, %

17%51%40%11%
Quarterly
USDQ3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

773.0k1.5m2.0m2.8m1.3m2.7m3.0m1.8m400.0k300.0k800.0k700.0k

Cost of goods sold

644.0k823.0k990.0k1.3m769.0k1.7m1.4m1.2m679.0k412.0k541.0k423.0k

Gross profit

129.0k649.0k1.0m1.5m531.0k968.0k1.6m543.0k(279.0k)(112.0k)259.0k277.0k

Gross profit Margin, %

17%44%51%53%41%36%53%31%(70%)(37%)32%40%
show all
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

73.0m21.1m21.2m14.1m

Accounts Receivable

2.9m4.2m870.0k285.0k

Prepaid Expenses

1.7m2.5m2.0m

Inventories

827.0k1.4m1.6m1.9m
Quarterly
USDQ3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

2.3m41.7m5.8m12.1m33.5m24.2m21.6m24.7m13.5m19.4m8.9m6.8m

Accounts Receivable

1.0m1.8m2.5m2.6m3.0m2.8m1.8m447.0k238.0k461.0k

Prepaid Expenses

2.9m1.0m705.0k1.0m1.2m857.0k909.0k1.5m954.0k683.0k

Inventories

438.0k928.0k747.0k911.0k1.9m1.8m2.0m1.9m2.1m2.0m1.4m
show all
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(20.5m)(34.8m)(37.4m)(23.7m)

Depreciation and Amortization

192.0k479.0k

Inventories

(464.0k)(591.0k)(162.0k)12.0k

Accounts Payable

46.0k624.0k70.0k(543.0k)
Quarterly
USDQ3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(13.0m)(7.7m)(15.5m)(24.6m)(12.1m)(21.9m)(28.6m)(8.3m)(15.1m)(18.8m)(5.3m)(9.4m)

Depreciation and Amortization

142.0k66.0k136.0k221.0k129.0k

Inventories

(75.0k)(101.0k)80.0k(84.0k)(449.0k)(424.0k)(537.0k)102.0k(157.0k)(117.0k)(326.0k)(524.0k)

Accounts Payable

519.0k217.0k58.0k534.0k1.1m275.0k135.0k(137.0k)(191.0k)(724.0k)422.0k405.0k
show all
USDQ3, 2016

Financial Leverage

-0.3 x
Show all financial metrics

Obalon Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

Learn more about about our premium products
SecurityScorecard logo

Obalon Therapeutics Online and Social Media Presence

Obalon Therapeutics's Trends

Embed Graph

Obalon Therapeutics News and Updates

March 25, 2020

Obalon Therapeutics explores strategic alternatives as coronavirus hits

Obalon Therapeutics said on Wednesday it was exploring financial and strategic alternatives due to the uncertainty regarding COVID-19 and restriction on elective procedures, which have had a direct impact on its business.
September 28, 2019

Obalon (OBLN) Alert: Johnson Fistel Announces Shareholder Class Action Against Obalon Therapeutics Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses?

SAN DIEGO, Sept. 28, 2019 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of Obalon Therapeutics, Inc. (NASDAQ: OBLN) ("Obalon" or the "Company") against certain of its officers and directors. Specifically, a class action lawsuit pending in the United...
December 27, 2018

Obalon Therapeutics, Inc. Announces Two Agreements To Provide Up To $30 Million of Capital

SAN DIEGO, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has entered into …
September 26, 2018

Global Intragastric Balloons Market 2018-2022 - Key Vendors are Allurion Technologies, Apollo Endosurgery, Helioscopie, Obalon Therapeutics, ReShape Lifesciences & Spatz FGIA

DUBLIN, Sept. 26, 2018 /PRNewswire/ -- The "Global Intragastric Balloons Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global Intragastric Balloons Market to grow at a CAGR of 25.18% during the period 2018-2022. The report has been prepared based on an...
August 23, 2018

Obalon Therapeutics to Raise $10 Million in Private Placement

SAN DIEGO, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN) a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has entered into a…
May 12, 2018

Obalon Therapeutics' (OBLN) CEO Andrew Rasdal on Q1 2018 Results - Earnings Call Transcript

Obalon Therapeutics Blogs

Show more

 Obalon Therapeutics Frequently Asked Questions

  • When was Obalon Therapeutics founded?

    Obalon Therapeutics was founded in 2008.

  • Who are Obalon Therapeutics key executives?

    Obalon Therapeutics's key executives are Mark Brister and Nooshin Hussainy.

  • How many employees does Obalon Therapeutics have?

    Obalon Therapeutics has 34 employees.

  • What is Obalon Therapeutics revenue?

    Latest Obalon Therapeutics annual revenue is $3.3 m.

  • What is Obalon Therapeutics revenue per employee?

    Latest Obalon Therapeutics revenue per employee is $97.1 k.

  • Who are Obalon Therapeutics competitors?

    Competitors of Obalon Therapeutics include UroMems, AristaMD and Qool Therapeutics.

  • Where is Obalon Therapeutics headquarters?

    Obalon Therapeutics headquarters is located at 5421 Avenida Encinas f, Carlsbad.

  • Where are Obalon Therapeutics offices?

    Obalon Therapeutics has an office in Carlsbad.

  • How many offices does Obalon Therapeutics have?

    Obalon Therapeutics has 1 office.